Genocea Biosciences is a biopharmaceutical company developing T cell-directed vaccines and immunotherapies to treat infectious diseases and cancer. The company uses its proprietary ATLAS&#x2122; antigen identification platform to build a pipeline of immunotherapies that currently includes GEN-003, an immunotherapy for genital herpes, and GEN-009, its first neoantigen cancer vaccine, for which an Investigational New Drug application filing is expected by the end of 2017. Genocea Biosciences was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.
